Investigation of Serum Phoenixin-14 Concentration in Pregnant Women Diagnosed with Hyperemesis Gravidarum

Abstract

Objective We aimed to investigate the relationship between the hyperemesis gravidarum (HG) and maternal serum phoenixin-14 (PNX-14) concentrations.

Materials and methods This cross-sectional study was conducted with 88 pregnant women who applied to the Umraniye Training and Research Hospital Gynecology and Obstetrics Clinic between February 2022 and October 2022. The HG group consisted of 44 pregnant women diagnosed with HG between the 7th and 14th gestational weeks, and the control group consisted of 44 healthy pregnant women matched with the HG group in terms of age, BMI, and gestational week. Demographic characteristics, ultrasound findings, and laboratory outcomes were noted. The two groups were compared in terms of maternal serum PNX-14 concentrations.

Results Gestational age at blood sampling for PNX-14 was similar in both groups (p=1.000). While maternal serum PNX-14 concentration was 85.5 pg/ml in the HG group, it was 71.3 pg/ml in the control group (p=0.012). ROC analysis was performed to determine the value of maternal serum PNX-14 concentration in terms of predicting HG. AUC analysis of maternal serum PNX-14 for HG estimation was 0.656 (p=0.012, 95% CI=0.54–0.77). The optimal cutoff value for maternal serum PNX-14 concentration was determined as 79.81 pg/ml with 59% sensitivity and 59% specificity.

Conclusion In this study, maternal serum PNX-14 concentration was found to be higher in pregnant women with HG, which indicates that high serum PNX-14 concentrations may have an anorexigenic effect on food intake in pregnancy. Concentrations of other PNX isoforms in HG and changes in PNX concentrations in pregnant women with HG who regained weight after treatment remain to be investigated.

Key words

Hyperemesis gravidarum - nausea - phoenixin - pregnancy - vomiting

Publication History

Received: 18 December 2022

Accepted: 04 April 2023

Article published online:
22 May 2023

• References

• 1 Jennings LK, Mahdy H. Hyperemesis Gravidarum. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022
• 2 Jansen LAW, Koot MH, van’t Hooft J. et al. The windsor definition for hyperemesis gravidarum: A multistakeholder international consensus definition. Eur J Obstet Gynecol Reprod Biol 2021; 266: 15-22 DOI: 10.1016/j.ejogrb.2021.09.004.
• 3 Lowe SA, Steinweg KE. Review article: Management of hyperemesis gravidarum and nausea and vomiting in pregnancy. Emerg Med Australas 2022; 34: 9-15 DOI: 10.1111/1742-6723.13909.
• 4 Lacasse A, Rey E, Ferreira E. et al. Epidemiology of nausea and vomiting of pregnancy: prevalence, severity, determinants, and the importance of race/ethnicity. BMC Pregnancy Childbirth 2009; 9: 26 DOI: 10.1186/1471-2393-9-26.
• 5 Fejzo MS, Sazonova OV, Sathirapongsasuti JF. et al. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat Commun 2018; 9: 1178 DOI: 10.1038/s41467-018-03258-0.
• 6 Vikanes A, Skjaerven R, Grjibovski AM. et al. Recurrence of hyperemesis gravidarum across generations: population based cohort study. BMJ 2010; 340: c2050 DOI: 10.1136/bmj.c2050.
• 7 Yosten GLC, Lyu R-M, Hsueh AJW. et al. A novel reproductive peptide, phoenixin. J Neuroendocrinol 2013; 25: 206-215 DOI: 10.1111/j.1365-2826.2012.02381.x.
• 8 Billert M, Rak A, Nowak KW. et al. Phoenixin: More than reproductive peptide. Int J Mol Sci 2020; 21: 8378 DOI: 10.3390/ijms21218378.
• 9 Liang H, Zhao Q, Lv S. et al. Regulation and physiological functions of phoenixin. Front Mol Biosci 2022; 9: 956500 DOI: 10.3389/fmolb.2022.956500.
• 10 Lyu R-M, Huang X-F, Zhang Y. et al. Phoenixin: A novel peptide in rodent sensory ganglia. Neuroscience 2013; 250: 622-631 DOI: 10.1016/j.neuroscience.2013.07.057.
• 11 Cowan A, Lyu R-M, Chen Y-H. et al. Phoenixin: A candidate pruritogen in the mouse. Neuroscience 2015; 310: 541-548 DOI: 10.1016/j.neuroscience.2015.09.055.
• 12 Treen AK, Luo V, Belsham DD. Phoenixin activates immortalized GnRH and kisspeptin neurons through the novel receptor GPR173. Mol Endocrinol 2016; 30: 872-888 DOI: 10.1210/me.2016-1039.
• 13 Schalla M, Prinz P, Friedrich T. et al. Phoenixin-14 injected intracerebroventricularly but not intraperitoneally stimulates food intake in rats. Peptides 2017; 96: 53-60 DOI: 10.1016/j.peptides.2017.08.004.
• 14 Pałasz A, Tyszkiewicz-Nwafor M, Suszka-Świtek A. et al. Longitudinal study on novel neuropeptides phoenixin, spexin and kisspeptin in adolescent inpatients with anorexia nervosa – association with psychiatric symptoms. Nutr Neurosci 2021; 24: 896-906 DOI: 10.1080/1028415X.2019.1692494.
• 15 Billert M, Wojciechowicz T, Jasaszwili M. et al. Phoenixin-14 stimulates differentiation of 3T3-L1 preadipocytes via cAMP/Epac-dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids 2018; 1863: 1449-1457 DOI: 10.1016/j.bbalip.2018.09.006.
• 16 Schalla MA, Stengel A. Phoenixin-a pleiotropic gut-brain peptide. Int J Mol Sci 2018; 19: 1726 DOI: 10.3390/ijms19061726.
• 17 Friedrich T, Schalla MA, Scharner S. et al. Intracerebroventricular injection of phoenixin alters feeding behavior and activates nesfatin-1 immunoreactive neurons in rats. Brain Res 2019; 1715: 188-195 DOI: 10.1016/j.brainres.2019.03.034.
• 18 Rocca C, Scavello F, Granieri MC. et al. Phoenixin-14: detection and novel physiological implications in cardiac modulation and cardioprotection. Cell Mol Life Sci 2018; 75: 743-756 DOI: 10.1007/s00018-017-2661-3.
• 19 Wang M, Deng S-P, Chen H-P. et al. Phoenixin participated in regulation of food intake and growth in spotted scat, Scatophagus argus. Comp Biochem Physiol B Biochem Mol Biol 2018; 226: 36-44 DOI: 10.1016/j.cbpb.2018.07.007.
• 20 Rajeswari JJ, Blanco AM, Unniappan S. Phoenixin-20 suppresses food intake, modulates glucoregulatory enzymes, and enhances glycolysis in zebrafish. Am J Physiol Regul Integr Comp Physiol 2020; 318: R917-R928 DOI: 10.1152/ajpregu.00019.2020.